Mario serves as Executive Chairman of Orthonika, having previously led the company as CEO since formation. He is one of the key inventors behind the technology. Previously, Mario was a venture capitalist, most recently as a Venture Partner with Fort Rock Capital where he served on the Boards of vasopharm GmbH and GNS Healthcare. Prior to that he was part of the life sciences investment team at Entrepreneurs Fund whose notable investments include Optinose (listed on the Nasdaq) and Prosonix (acquired by Circassia).  Mario started his career in strategy consulting with Deallus Consulting.

Mario holds a Postgraduate in Genomic Medicine, a Ph.D. in Biomedical Engineering and a First-Class Honours MEng Degree in Mechanical Engineering with a focus on Biomedical, all from Imperial College London. Mario’s academic research focused on early diagnosis of osteoarthritis, regenerative medicine techniques and orthopaedic biomechanics. He is an inventor in several patents and has published in international peer reviewed scientific journals. Mario is also CEO and Co-Founder of Orexia Therapeutics (merged with Centessa Pharmaceuticals, NASDAQ: CNTA) and serves on the Board of Embody Orthopaedics and on the Strategic Advisory Board of G3 Therapeutics.

Professor Amis is the Chair of Orthopaedic Biomechanics at Imperial College London as well as the Head of the Medical Engineering. He has 40 years of research in orthopaedic biomechanics, including the design of artificial human joints, tendons and ligaments and the mechanical analyses of biological systems and structures. He has over 300 peer-reviewed journal publications. In addition to research work, Andrew has acted as a consultant and expert witness for a number of areas of work, including implant design, failures of orthopaedic implants and industrial injuries.

Professor Cobb is the Chair in Orthopaedics at Imperial College London and is also the Founder of Acrobot, the worlds first haptic based robotic assistant. He is a Civilian advisor in orthopaedics to the Royal Air Force and is on the staff of King Edward VII hospital for Officers as well as being the Orthopaedic Surgeon to Her Majesty the Queen. Justin is a Graduate of Medicine at Magdalen College,Oxford. Justin’s research group is known to have secured £80m for the development of The Michael Uren Biomedical Engineering Hub which will enable engineers and medics to come together and develop new technologies.

Max Graziosi has worked for over 20 years in Capital Markets in a number of financial institutions in London including Credit Suisse, Bear Sterns and Nomura. He recently left Bank of America Merrill Lynch where he was a Managing Director, EMEA Chief Operating Officer for Fixed Income Currencies and Commodities. He has a vast experience in investing across many asset classes and industry sectors. He is an angel investor in a number of projects including The Kinase Project with Imperial Innovations Group plc, advancing LMTK3 as a therapeutic target for breast cancer and Maternal Matters Plc, a service providing social care to single mothers and their infants.

Dominique is COO at Orthonika since co-founding the company in 2015. She has wide experience of product, business and company development, starting as a Research Scientist for Unilever in the team that launched Clear Blue diagnostics through its Unipath subsidiary. She was Business Development Manager for GSK’s Wellcome Diagnostics subsidiary, licensing-in new product lines and transitioning the business through acquisition by Murex and subsequent 10x sale to Abbott. In 1999 she joined Imperial Innovations to build a portfolio of spin-outs such as Acrobot (sold to Stryker) and Protexeon (sold to Air Products) and became Head of Life Sciences Technology Transfer in anticipation of the company’s IPO in 2006. In 2009 she left Imperial to become CEO at London Genetics, raising £2m to deliver pharmacogenetic services in clinical development, and has since worked in various biotech executive and non-executive roles, including 2 years on the board of the BioIndustry Association and 5 years as a Trustee of the Genetics Society. She holds a BSc in Life Sciences and an MBA with a focus on Technology Entrepreneurship from Imperial College London. She is an LESi Certified Licensing Professional.